DBV Technologies S.A.

DBVT | $0.6884 4.15% 3.98% 120K

(0.0% 1d) (-15.9% 1m) (-58.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (10.47% volume)
Earnings Calendar:
Market Cap: $ 132,770,839
http://www.dbv-technologies.com
Sec Filling | Patents | 319 employees

(FR) DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. It focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.

immunotherapy clinical trials

add to watch list Paper trade email alert is off

Press-releases

Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024
Published: 2024-04-04 (Crawled : 21:00) - globenewswire.com
DBVT | $0.6884 4.15% 3.98% 120K

Health Technology

| -5.71% | O: -4.84% H: 15.76% C: 14.1%
company total

DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document
Published: 2024-03-08 (Crawled : 14:30) - globenewswire.com
DBVT | $0.6884 4.15% 3.98% 120K

Health Technology

| -20.1% | O: -0.73% H: 5.96% C: 4.63%
report universal

DBV Technologies Reports Full Year 2023 Financial Results and Business Update
Published: 2024-03-07 (Crawled : 22:00) - globenewswire.com
DBVT | $0.6884 4.15% 3.98% 120K

Health Technology

| -20.1% | O: -0.73% H: 5.96% C: 4.63%
business year update financial results

DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024
Published: 2024-03-04 (Crawled : 22:00) - globenewswire.com
DBVT | $0.6884 4.15% 3.98% 120K

Health Technology

| -22.54% | O: -3.16% H: 4.22% C: 2.4%
report business year update financial results

DBV Technologies to Participate in Upcoming AAAAI 2024 Congress
Published: 2024-02-20 (Crawled : 22:00) - globenewswire.com
DBVT | $0.6884 4.15% 3.98% 120K

Health Technology

| -15.99% | O: -1.99% H: 7.29% C: 5.21%
congress

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
Published: 2024-01-16 (Crawled : 22:00) - globenewswire.com
DBVT | $0.6884 4.15% 3.98% 120K

Health Technology

| -24.26% | O: 1.69% H: 0.0% C: -2.95%
report contract

Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023
Published: 2023-12-04 (Crawled : 22:00) - globenewswire.com
DBVT | $0.6884 4.15% 3.98% 120K

Health Technology

| -5.71% | O: 4.29% H: 4.41% C: 1.85%
company total

DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers
Published: 2023-11-09 (Crawled : 22:00) - globenewswire.com
DBVT | $0.6884 4.15% 3.98% 120K

Health Technology

| -28.61% | O: 4.92% H: 2.06% C: -2.05%
peanut ongoing extension trial results

Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023
Published: 2023-11-06 (Crawled : 22:00) - globenewswire.com
DBVT | $0.6884 4.15% 3.98% 120K

Health Technology

| -34.0% | O: -2.0% H: 2.04% C: 0.0%
company total

DBV Technologies to Present New Data at ACAAI 2023
Published: 2023-11-02 (Crawled : 21:00) - globenewswire.com
DBVT | $0.6884 4.15% 3.98% 120K

Health Technology

| -34.0% | O: 4.0% H: 0.0% C: -0.96%

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001209191-23-056410	4	2023-11-22	2023-11-20	Buy	A	113000	113000
0001209191-23-056410	4	2023-11-22	2023-11-20	Buy	A	19000	19000
0001209191-23-056409	4	2023-11-22	2023-11-20	Buy	A	806672	806672